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The 5alpha-reductase type 1, but not
type 2, gene is expressed in anagen
hairs plucked from the vertex area of
the scalp of hirsute women and normal
individuals
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Abstract
The aim of the present study was to determine the expression of the
genes for type 1 (SDR5A1) and type 2 (SDR5A2) 5α-reductase
isoenzymes in scalp hairs plucked from 33 hirsute patients (20 with
polycystic ovary syndrome and 13 with idiopathic hirsutism) and
compare it with that of 10 men and 15 normal women. SDR5A1 and
SDR5A2 expression was estimated by RT-PCR using the gene of the
ubiquitously expressed protein ß2-microglobulin as an internal con-
trol. The results are expressed as arbitrary units in relation to ß2-
microglobulin absorbance (mean ± SEM). SDR5A2 expression was
not detected in any hair samples analyzed in this study. No differences
were found in SDR5A1 mRNA levels between men and normal
women (0.78 ± 0.05 vs 0.74 ± 0.06, respectively). SDR5A1 gene
expression in the cells of hair plucked from the scalp of normal women
(0.85 ± 0.04) and of women with polycystic ovary syndrome (0.78 ±
0.05) and idiopathic hirsutism (0.80 ± 0.06) was also similar. These
results indicate that SDR5A1 gene expression in the follicular keratin-
ocytes from the vertex area of the scalp seems not to be related to the
differences in hair growth observed between normal men and women
and hirsute patients. Further studies are needed to investigate the
expression of the 5α-reductase genes in other scalp follicular compart-
ments such as dermal papillae, and also in hair follicles from other
body sites, in order to elucidate the mechanism of androgen action on
the hair growth process and related diseases.
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Introduction
Androgens are the main regulators of
human hair growth and are associated with
one of the major clinical hair growth disor-
ders, namely hirsutism. This condition cor-
responds to excessive body hair growth in
women with a male pattern of body hair
distribution. The presence of hirsutism can
signal conditions associated with increased
androgen secretion by ovaries and/or adrenals
such as polycystic ovary syndrome (PCOS),
androgen-secreting tumors, and nonclassic
adrenal hyperplasia or can result from pe-
ripheral hypersensitivity to circulating an-
drogens (idiopathic hirsutism, IH) (1-3). Al-
though in general this condition is not life
threatening, it is greatly distressing to pa-
tients and has a significant negative psycho-
social impact. Investigating the effects of
androgens on hair growth in the presence of
hirsutism should improve our knowledge of
human hair follicle biology.
The effect of all active androgens on target
cells is mediated by their binding to the same
nuclear androgen receptor. Previous studies
on androgen resistance syndromes have re-
vealed the importance of the androgen recep-
tor for androgen-dependent hair growth (4-6).
More recently, an increased androgen binding
capacity was observed in scalp hair cells of
balding men (7). However, no consistent dif-
ference has been found thus far in the number
or function of the androgen receptor in hirsute
patients compared to normal subjects (8,9).
Hair follicles have autonomous control
over androgen metabolism, adjusting the pro-
duction and degradation of steroid hormones
according to local requirements (10). Under
normal conditions, 5α-reductase has a key
role in the action of androgens on hair fol-
licles, converting testosterone to the more
potent androgen dihydrotestosterone (11,12).
Studies of molecular cloning have character-
ized two genes that encode the type 1 and
type 2 5α-reductase isoenzymes (13,14). The
5α-reductase isoenzyme predominant in the
skin is type 1 (SDR5A1) (15), which has
60% homology with 5α-reductase type 2
(SDR5A2) that is characteristic of the pros-
tate gland (14). An increase in 5α-reductase
activity was demonstrated in genital and pu-
bic skin fibroblasts from hirsute patients in
comparison to the skin of normal women
(8,16). These studies have reported an in-
crease in 5α-reductase activity even in IH,
which is characterized by the absence of
elevated plasma androgen levels (17). More-
over, pubic skin of hirsute patients expresses
the same SDR5A1 isoform as pubic skin of
normal subjects, whereas SDR5A2 is mainly
expressed in genital skin from both normal
subjects and hirsute patients (18). However,
the physiological role of 5α-reductase isoen-
zymes is not completely understood and their
distribution in different skin compartments
is still unclear. Some immunohistochemical
and enzyme activity studies have suggested
a predominant expression of SDR5A1 en-
zyme in sebaceous glands, but also in sweat
glands, epidermal cells, root sheath and der-
mal papilla cells from hair follicles (19-21),
whereas SDR5A2 is only expressed in these
compartments at very low levels. In contrast,
other studies have demonstrated a different
distribution of these isoenzymes inside the
pilosebaceous unit (22-24). There seems to
be a higher distribution of SDR5A1 in hair
follicle compartments compared to SDR5A2.
Furthermore, since root sheath keratinocytes
show high expression of the SDR5A1 gene,
they probably play an important role in an-
drogen metabolism in hair follicles.
The aim of the present study was to assess
the expression of the SDR5A1 and SDR5A2
genes in hair root sheath cells of the vertex area
of scalp from hirsute patients and compare it
with normal subjects of both sexes.
Patients and Methods
Subjects
The study population included women1449
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consulting for hirsutism seen consecutively
during a 6-month period at the Gynecologi-
cal Endocrinology Unit of Hospital de Clíni-
cas de Porto Alegre, Brazil. Thirty-three pa-
tients ranging in age from 12 to 42 years
were selected for the study. Twenty patients
were diagnosed as having PCOS and 13 as
having IH. The diagnosis of PCOS was based
on the physical features of hyperandrogenism,
disturbed menstrual cycles, elevated serum
luteinizing hormone (LH) levels or LH/
follicle-stimulating hormone ratio, increased
levels of total testosterone and/or free andro-
gen index (FAI), ultrasound evidence of bi-
lateral enlarged polycystic ovaries (25,26),
and absence of ovarian or adrenal neoplasm
or Cushing’s syndrome. IH was diagnosed
as previously described (27) in hirsute pa-
tients with regular ovulatory cycles (luteal
phase progesterone levels higher than 3.8
ng/ml), normal androgen levels, and without
any known underlying disease.
Late-onset (nonclassic) congenital adre-
nal hyperplasia patients were not considered
for the study on the basis of a high plasma
level of 17-hydroxyprogesterone (>5 ng/ml)
and/or its marked increase after ACTH stim-
ulation (>12 ng/ml) (28,29). Patients with
hyperprolactinemia (serum prolactin levels
higher than 20 µg/l on two different occa-
sions) were also excluded.
Fifteen normal women with regular men-
strual cycles aged 16-37 years and ten men
aged 16-29 years were also selected for the
study, which was approved by the Ethics
Committee of Hospital de Clínicas de Porto
Alegre. Informed consent was obtained from
each subject. None of the subjects had re-
ceived any drugs known to interfere with
androgen, estrogen or gonadotropin serum
levels for at least 3 months before the study.
SDR5A1 and SDR5A2 mRNA levels
were estimated by the reverse transcription-
polymerase chain reaction (RT-PCR) in hair
cells plucked from the vertex portion of the
scalp of normal men, normal women and
hirsute patients.
Study protocol
Anthropometric measurements included
body weight, height and body mass index
(BMI = current measured weight in kg di-
vided by height in m2). Hirsutism score was
graded by the Ferriman-Gallwey method
(30), excluding the lower leg and forearm
areas.
Hormonal assessment was performed
between day 2 and 10 of the menstrual cycle
or on any day when the patients were amen-
orrheic. After an overnight fast, blood
samples were drawn from an antecubital
vein for determination of LH, sex hormone-
binding globulin (SHBG) and total testoster-
one. All samples were obtained between 8
and 10 am. The FAI was estimated by divid-
ing total testosterone (nmol/l) by SHBG
(nmol/l) x 100.
Assays
Total testosterone was measured by
double-antibody radioimmunoassay (ICN,
Costa Mesa, CA, USA), with an assay detec-
tion limit of 0.04 ng/ml and intra- and inter-
assay coefficient of variance (CV) of 10 and
15%, respectively; SHBG was measured by
an immunochemiluminometric assay (ICMA;
DPC, Los Angeles, CA, USA), with a detec-
tion limit of 0.2 nmol/l, and intra- and inter-
assay CV of 5.0 and 8.0%, respectively. LH
was measured by ICMA, with a detection
limit of 0.7 mIU/ml and intra- and interassay
CV of 5.2 and 8.0%, respectively.
RT-PCR protocol
Plucked anagen hairs were collected from
the vertex of the scalp of all subjects and
were immediately frozen in liquid nitrogen
and transported to the laboratory for assays.
The extraction of total RNA and the synthe-
sis of cDNA were carried out as previously
described (31). The plucked hair roots were
homogenized in phenol-guanidine isothio-1450
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cyanate (Trizol, Gibco-BRL, Gaithersburg,
MD, USA). Total RNA was extracted with
chloroform and precipitated with isopropanol
by 12,000 g centrifugation at 4ºC. The RNA
pellet was washed twice with 75% ethanol,
resuspended in diethylpyrocarbonate-treated
water, and quantified by absorbance at 260
nm.
First strand cDNA was synthesized from
5 µg total RNA for all reactions using the
SuperScript Preamplification System (Gibco-
BRL). After denaturing the template RNA
and primers at 70ºC for 10 min, reverse
transcriptase was added in the presence of
20 mM Tris-HCl, pH 8.4, plus 50 mM KCl,
2.5 mM MgCl2, 0.5 mM dNTP mix and 10
mM dithiothreitol, and incubated at 42ºC for
55 min. The mixture was heated to 70ºC to
stop the reaction and then incubated with E.
coli RNase for 20 min at 37ºC to destroy
untranscribed RNA. The template (cDNA)
used in the different PCR assays was ob-
tained from the same reverse transcription
reaction. PCR was carried out in a final
volume of 50 µl. Two microliters of the first
strand synthesis reaction (with an expected
cDNA yield of 10 ng) was denatured at 94ºC
for 3 min (2 min only for ß2-microglobulin)
in the presence of 20 mM Tris-HCl, pH 8.4,
plus 50 mM KCl and 1.5 mM MgCl2. After
this hot start, 1.25 U of Taq DNA poly-
merase was added together with the same
Tris-HCl buffer, 1.5 mM MgCl2, 0.4 µM
sense and antisense primers and 0.2 mM
dNTP mix.
A 368-bp fragment of the SDR5A1 (24)
and a 566-bp fragment of the SDR5A2 (14)
cDNA sequence were amplified using prim-
ers designed to span intron-exon borders in
order to prevent the amplification of any
contaminating genomic DNA. A 623-bp
cDNA fragment corresponding to the ubiq-
uitously expressed protein ß2-microglobulin
(32) was amplified to normalize the cDNA
amounts in each sample. The cDNA se-
quences of SDR5A1 and SDR5A2 and ß2-
microglobulin primers are listed in Table 1.
PCR was standardized by testing a number
of cycles (20 to 45) and amplification was
performed in the linear range. Final PCR
conditions were as follows: 35 cycles (45 s at
94ºC, 45 s at 60ºC, 90 s at 72ºC, 10 min at
72ºC) for SDR5A1, 40 cycles (1 min at
94ºC, 1 min at 65ºC, 2 min at 72ºC, 5 min at
72ºC) for SDR5A2, and 30 cycles (1 min at
94ºC, 1 min at 55ºC, 1 min at 72ºC, 5 min at
72ºC) for ß2-microglobulin. cDNA from dis-
sociated cells of human prostate gland was
used as a positive control for all PCR reac-
tions. No cDNA was added to the negative
reactions. A sample of the PCR mixture (15
µl) was size-fractionated on 1.5-2.0% aga-
rose gel stained with ethidium bromide, run
Table 1. Sequence of the primers related to SDR5A1, SDR5A2 and ß2-microglobulin
cDNA sequences and expected sizes of amplified fragments.
Gene Sequence (5'-3') Size of fragment
(reference)
SDR5A1
Sense TGGCGCTTCTCTATGGACTT 368 bp (21)
Antisense GGAAGCAACACTGCAGTTGA
SDR5A2
Sense TACTTCTGGGCCTCTTCTGCG 566 bp (14)
Antisense TTTCATCAGCATTGTGGGAGC
ß2-microglobulin
Sense ATCCAGCGTACTCCAAAGATTCAG 623 bp (32)
Antisense AAATTGAAAGTTAACTTATGCACGC
Table 2. Clinical and hormonal data for hirsute patients with polycystic ovary syn-
drome (PCOS) and idiopathic hirsutism (IH).
PCOS IH Normal values
Age (years)a 23.0 ± 1.2 24.3 ± 1.7 -
BMI (kg/m2)a 30.7 ± 1.4 26.8 ± 1.1* -
Clinical score for hirsutisma 15.1 ± 1.3 13.9 ± 0.9 <8
Testosteronea (ng/ml) 0.89 ± 0.07 0.64 ± 0.06* 0.20-0.81
FAIa 15.3 ± 1.73 8.8 ± 1.34* 5.50-11.20
SHBGb (nmol/l) 24.4 (13.3-37.3) 33.9 (22.5-45.2) 20-118
LHb (IU/l) 4.6 (2.1-9.1) 2.7 (2.1-6.6) 1.6-8.3
aData are reported as mean ± SEM. bValues are reported as median and 95% confi-
dence interval. BMI, body mass index; FAI, free androgen index; SHBG, sex hormone-
binding globulin; LH, luteinizing hormone. *P < 0.05 compared to PCOS patients
(aANOVA followed by the Duncan test; bMann-Whitney test).1451
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at 100 V and visualized under UV light. The
expected bands were quantified by densito-
metric analysis using an image-processing
system (ImageMaster VDS, Pharmacia
Biotech, Uppsala, Sweden).
Statistical analysis
Data are reported as means ± SEM, un-
less otherwise noted. Group means were
compared by the Student t-test or by one-
way analysis of variance (ANOVA) followed
by the Duncan test, and median values were
compared by the Mann-Whitney test. Differ-
ences were considered to be statistically sig-
nificant at P < 0.05. All analyses were per-
formed using the Statistical Packages for the
Social Sciences (SPSS, Inc., Chicago, IL,
USA).
Results
Table 2 summarizes the anthropometric
and hormonal data for patients with PCOS
and IH. No significant differences were ob-
served between the two groups of hirsute
patients regarding age or clinical score for
hirsutism. However, hirsute patients with
PCOS presented higher BMI and showed
significantly higher levels of testosterone,
FAI and LH than the IH group. SHBG con-
centrations were lower in the PCOS group
than in the IH group.
SDR5A2 gene expression was not de-
tected in any scalp hair samples analyzed by
RT-PCR in the present study (Figure 1).
Figure 2 shows SDR5A1 mRNA levels
in hair cells plucked from the scalp of nor-
mal subjects. SDR5A1 expression, presented
as arbitrary units in relation to ß2-micro-
globulin absorbance, was similar in men
(0.78 ± 0.05) and normal women (0.74 ±
0.06). Furthermore, no significant differences
were observed in follicular keratinocyte
SDR5A1 expression between normal women
(0.85 ± 0.04) and the PCOS (0.78 ± 0.04) or
IH (0.80 ± 0.06) hirsute groups (Figure 3).
Figure 2. Representative gel showing SDR5A1 mRNA levels determined by RT-PCR in hair
cells plucked from the scalp of men (1 to 7) and normal women (8 to 14). The 368-bp
fragment corresponds to SDR5A1 (5α-R1) and the 623-bp fragment corresponds to ß2-
microglobulin (ß2-m). RT-PCR products were visualized on agarose gel stained with ethi-
dium bromide. + = positive control.
623 bp
368 bp
ß2-m
5α-R1
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 +
ß2-m
5α-R1
ß2-m
5α-R1
ß2-m
5α-R1
Figure 3.         Representative gel showing SDR5A1 mRNA levels determined by RT-PCR in hair
cells plucked from the scalp of normal women (1 to 14) and of both groups of hirsute
patients (PCOS: 15 to 26; IH: 27 to 35). The 368-bp fragment corresponds to SDR5A1 (5α-
R1), and the 623-bp fragment corresponds to ß2-microglobulin (ß2-m). RT-PCR products
were visualized on agarose gel stained with ethidium bromide.
623 bp
368 bp
623 bp
368 bp
623 bp
368 bp
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14
M1 51 61 71 81 92 02 12 22 32 42 5 2 6
M2 72 82 93 03 13 23 3 3 43 5
Figure 1. Representative agarose gel stained with ethidium bromide showing no expres-
sion of SDR5A2 mRNA by RT-PCR in hair cells plucked from the scalp of men (1 to 9),
normal women (10 to 17) and hirsute patients: PCOS group (18 to 31) and IH group (32 to
39). The 566-bp fragment corresponds to SDR5A2 (5α-R2) and the 623-bp fragment
corresponds to ß2-microglobulin (ß2-m). SDR5A2 amplification was visualized only in
dissociated prostatic cells used as positive control (+).
623 bp
566 bp
623 bp
566 bp
ß2-m
5α-R2
ß2-m
5α-R2
ß2-m
5α-R2
623 bp
566 bp
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
M1 8 1 92 02 12 22 32 42 52 62 72 82 93 0 3 1
M3 23 334 35 36 37 38 39 +1452
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Discussion
Although skin 5α-reductase activity is
associated with hirsutism, the specific role
and the identification of the isoenzyme in-
volved in this clinical hair growth condition
still need to be better defined. In the present
study, we investigated mRNA expression of
both types of 5α-reductase in plucked anagen
scalp hair cells of hirsute patients.
The SDR5A1 gene was expressed in
plucked hair cells obtained from the vertex
of the scalp of normal subjects. Other studies
have demonstrated similar results, even when
SDR5A1 mRNA was investigated in cul-
tured follicular keratinocytes (24,33). Plucked
anagen hairs are mainly constituted by kerat-
inocyte cells forming both outer and inner
root sheaths. The connective tissue sheath,
the lower bulb, the dermal papilla cells and
the sebaceous gland are absent in plucked
hairs. Therefore, our data confirm the gene
expression of SDR5A1 in follicular keratin-
ocytes, and are in agreement with others,
which showed 5α-reductase immunoreac-
tivity in root sheath cells of hair follicles
(20,23).
In the present study, SDR5A1 mRNA
levels from plucked scalp hairs did not differ
between normal men and women. Previous
studies have also described a similar 5α-
reductase activity in hair follicles from men
and women (12,34). In contrast, a higher 5α-
reductase activity in pubic skin samples was
detected in normal men than in normal
women (1). Taken together, these results
suggest that in normal individuals 5α-reduc-
tase regulation seems to differ between folli-
cular keratinocytes of scalp and pubic skin
fibroblasts.
Scalp hair follicle cells seem not to be the
main target of hirsutism. However, there are
some ethical difficulties in obtaining samples
from the face of hirsute patients. Further-
more, there are only few literature reports
about the molecular mechanisms of scalp
hair follicle cells in the presence of hirsutism
(9). The scalp region is a well-known andro-
gen-sensitive site in both sexes and it is
relatively easy to obtain a sample of scalp
hairs. Therefore, it is interesting to investi-
gate some aspects of androgen metabolism
in plucked hair cells from the scalp, particu-
larly when it is possible to compare subjects
with an endogenous exposure to higher
(PCOS) or normal (IH) circulating androgen
levels.
We did not observe any differences in
SDR5A1 mRNA levels in the follicular ker-
atinocytes either between hirsute patients
and normal women or between normal men
and women. Moreover, patients with high
serum androgen levels (PCOS group) pre-
sented the same SDR5A1 gene expression as
those with IH and normal androgen levels.
While SDR5A1 is the isoenzyme predomi-
nating in the skin (14), the present results
indicate that circulating androgens probably
do not contribute to SDR5A1 gene expres-
sion in scalp follicular keratinocytes, sug-
gesting that SDR5A1 is not the key isoen-
zyme in the local androgen metabolism of
scalp skin. On the other hand, the efficacy of
the 5α-reductase inhibitor finasteride in the
treatment of male pattern hair loss (35), as
well as in IH has been demonstrated (36,37).
Finasteride is an orally active inhibitor that
preferentially blocks 5α-reductase type 2,
but may also inhibit the type 1 isoenzyme,
causing a marked decline in dihydrotestos-
terone and 3α-androstenediol glucuronide
levels. It has neither affinity for the androgen
receptor nor androgenic, estrogenic, proges-
tational, or other steroidal effects (38). In
agreement with our results, these studies
indicated that 5α-reductase type 2 probably
has a more critical role in the hair growth
process and related clinical conditions.
The present results show that the SDR5A2
gene was not expressed in the follicular ker-
atinocytes from any subject, men or normal
women or hirsute patients. Previous studies
have described the preferential localization
of SDR5A2 mRNA and enzyme activity1453
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(39,40) in the dermal papilla cells, although
SDR5A2 immunoreactivity was also found
in the keratinocytes of hair follicle (20,22).
The apparent discrepancies in protein ex-
pression among these studies may be ex-
plained, at least in part, by the different
methods of immunohistochemical analysis
of qualitative data. Concerning the absence
of SDR5A2 gene expression, described in
the present study, more sensitive methods of
gene expression analysis, e.g., real time PCR,
will possibly clarify this question in the future.
We have not investigated the gene ex-
pression of 5α-reductase isoenzymes in other
follicular compartments like dermal papillae
because these cells are not present in plucked
isolated hairs. The dermal papilla cells are
obtained only by excision biopsy, which is
an invasive and stressing method. However,
it will be very interesting to investigate 5α-
reductase isoenzymes in the dermal papilla
cells from hirsute patients, since it has been
suggested that these cells can be the direct
target of androgens in hair follicles, regulat-
ing the activity of the hair matrix, melano-
cytes and keratinocytes with paracrine sig-
nals (10).
SDR5A1 gene expression in the follicu-
lar keratinocytes from the vertex area of the
scalp seems not to be related to differences
in hair growth observed between normal
men and women and hirsute patients. More
investigations about the regulation of 5α-
reductase gene expression in hair follicle
cells at different body sites may help to
elucidate the intriguing mechanism of an-
drogen action on the hair growth process and
associated diseases.
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